VTGN Stock Overview
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS).
+ 2 more risks
VistaGen Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.16|
|52 Week High||US$2.69|
|52 Week Low||US$0.14|
|1 Month Change||-6.10%|
|3 Month Change||-83.14%|
|1 Year Change||-93.94%|
|3 Year Change||-85.60%|
|5 Year Change||-88.11%|
|Change since IPO||-99.68%|
Recent News & Updates
VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis
VistaGen Therapeutics (NASDAQ:VTGN) on Thursday said an independent group of biostatisticians recommended continuing its second phase 3 trial evaluating its nasal spray PH94B for the treatment of anxiety in adults with social anxiety disorder. The interim analysis of data from the late-stage trial, called PALISADE-2, concluded that the study should continue as planned, VTGN said in a statement. The independent biostatisticians reviewed unblinded data from the 140 subjects who completed the trial before VistaGen (VTGN) paused enrollment in July. The company noted that it did not have access to the unblinded data. VTGN said it would continue the study as recommended by the biostatisticians without any adjustment to its expected size of 208 subjects. Topline results from the late-stage trial is expected in H1 2023. VTGN stock +5.7% to $0.17 in morning trading.
|VTGN||US Biotechs||US Market|
Return vs Industry: VTGN underperformed the US Biotechs industry which returned -19.3% over the past year.
Return vs Market: VTGN underperformed the US Market which returned -18.8% over the past year.
|VTGN Average Weekly Movement||29.3%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: VTGN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 29% a week.
Volatility Over Time: VTGN's weekly volatility has increased from 17% to 29% over the past year.
About the Company
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company’s CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders.
VistaGen Therapeutics Fundamentals Summary
|VTGN fundamental statistics|
Is VTGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VTGN income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.29|
|Net Profit Margin||-5,669.78%|
How did VTGN perform over the long term?See historical performance and comparison
Is VTGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VTGN?
Other financial metrics that can be useful for relative valuation.
|What is VTGN's n/a Ratio?|
Price to Sales Ratio vs Peers
How does VTGN's PS Ratio compare to its peers?
|VTGN PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
MRKR Marker Therapeutics
CASI CASI Pharmaceuticals
SLS SELLAS Life Sciences Group
AGLE Aeglea BioTherapeutics
VTGN VistaGen Therapeutics
Price-To-Sales vs Peers: VTGN is expensive based on its Price-To-Sales Ratio (30.5x) compared to the peer average (14.8x).
Price to Earnings Ratio vs Industry
How does VTGN's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: VTGN is expensive based on its Price-To-Sales Ratio (30.5x) compared to the US Biotechs industry average (14x)
Price to Sales Ratio vs Fair Ratio
What is VTGN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||30.5x|
|Fair PS Ratio||42.9x|
Price-To-Sales vs Fair Ratio: VTGN is good value based on its Price-To-Sales Ratio (30.5x) compared to the estimated Fair Price-To-Sales Ratio (42.9x).
Share Price vs Fair Value
What is the Fair Price of VTGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate VTGN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VTGN's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is VistaGen Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VTGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VTGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VTGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VTGN's revenue (68.6% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: VTGN's revenue (68.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VTGN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has VistaGen Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VTGN is currently unprofitable.
Growing Profit Margin: VTGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VTGN is unprofitable, and losses have increased over the past 5 years at a rate of 30.1% per year.
Accelerating Growth: Unable to compare VTGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VTGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: VTGN has a negative Return on Equity (-129.84%), as it is currently unprofitable.
Discover strong past performing companies
How is VistaGen Therapeutics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: VTGN's short term assets ($55.0M) exceed its short term liabilities ($8.9M).
Long Term Liabilities: VTGN's short term assets ($55.0M) exceed its long term liabilities ($3.7M).
Debt to Equity History and Analysis
Debt Level: VTGN has more cash than its total debt.
Reducing Debt: VTGN's debt to equity ratio has reduced from 13.6% to 2.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VTGN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: VTGN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.3% each year
Discover healthy companies
What is VistaGen Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|VistaGen Therapeutics Dividend Yield vs Market|
|Company (VistaGen Therapeutics)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (VistaGen Therapeutics)||n/a|
Notable Dividend: Unable to evaluate VTGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VTGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VTGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VTGN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as VTGN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Shawn Singh (59 yo)
Mr. Shawn K. Singh, J.D. has been the Chief Executive Officer at VistaGen Therapeutics, Inc., since August 20, 2009. Mr. Singh serves as the Chief Business Officer and General Counsel at Cato Research Ltd....
CEO Compensation Analysis
|Shawn Singh's Compensation vs VistaGen Therapeutics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||US$1m||US$563k|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||US$1m||US$511k|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||US$934k||US$498k|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||US$951k||US$466k|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||US$1m||US$425k|
|Dec 31 2017||n/a||n/a|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||US$1m||US$385k|
|Dec 31 2016||n/a||n/a|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||US$2m||US$348k|
Compensation vs Market: Shawn's total compensation ($USD1.18M) is above average for companies of similar size in the US market ($USD772.75K).
Compensation vs Earnings: Shawn's compensation has been consistent with company performance over the past year.
Experienced Management: VTGN's management team is seasoned and experienced (6 years average tenure).
Experienced Board: VTGN's board of directors are considered experienced (6.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VTGN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|18 Aug 22||BuyUS$35,740||Jerry Gin||Individual||200,000||US$0.18|
|17 Aug 22||BuyUS$103,200||Shawn Singh||Individual||600,000||US$0.17|
|17 Aug 22||BuyUS$50,910||Reid Adler||Individual||300,000||US$0.17|
|12 Jul 22||SellUS$53,400||VR Adviser, LLC||Company||60,000||US$0.89|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.2%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
VistaGen Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: VistaGen Therapeutics, Inc.
- Ticker: VTGN
- Exchange: NasdaqCM
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$32.473m
- Shares outstanding: 206.84m
- Website: https://www.vistagen.com
Number of Employees
- VistaGen Therapeutics, Inc.
- 343 Allerton Avenue
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VTGN||NasdaqCM (Nasdaq Capital Market)||Yes||New Common Stock||US||USD||May 2011|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/06 00:00|
|End of Day Share Price||2022/10/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.